Fort Sheridan Advisors LLC Has $4.14 Million Position in Pfizer Inc. (NYSE:PFE)

Fort Sheridan Advisors LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 1.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 80,014 shares of the biopharmaceutical company’s stock after acquiring an additional 1,492 shares during the quarter. Pfizer accounts for 1.2% of Fort Sheridan Advisors LLC’s portfolio, making the stock its 16th largest position. Fort Sheridan Advisors LLC’s holdings in Pfizer were worth $4,142,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently bought and sold shares of PFE. PYA Waltman Capital LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at $31,000. Rinkey Investments acquired a new stake in shares of Pfizer in the fourth quarter valued at $32,000. Stuart Chaussee & Associates Inc. increased its stake in shares of Pfizer by 108.3% in the first quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 325 shares in the last quarter. Bivin & Associates Inc. acquired a new stake in shares of Pfizer in the fourth quarter valued at $37,000. Finally, Evolution Advisers Inc. increased its stake in shares of Pfizer by 309.3% in the first quarter. Evolution Advisers Inc. now owns 794 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 600 shares in the last quarter. 66.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 19th. Morgan Stanley decreased their price target on Pfizer from $52.00 to $49.00 and set an “equal weight” rating on the stock in a report on Friday, July 8th. Berenberg Bank set a $50.00 price target on Pfizer in a report on Friday, May 27th. Barclays raised their price target on Pfizer from $50.00 to $52.00 and gave the company an “equal weight” rating in a report on Monday, August 1st. Finally, SVB Leerink reduced their target price on Pfizer from $55.00 to $53.00 and set a “market perform” rating on the stock in a report on Friday, July 29th. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $57.50.

Insiders Place Their Bets

In other Pfizer news, SVP Jennifer B. Damico sold 4,218 shares of the business’s stock in a transaction that occurred on Tuesday, June 7th. The stock was sold at an average price of $53.96, for a total transaction of $227,603.28. Following the transaction, the senior vice president now owns 10,846 shares of the company’s stock, valued at approximately $585,250.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Jennifer B. Damico sold 4,000 shares of Pfizer stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $50.50, for a total transaction of $202,000.00. Following the completion of the transaction, the senior vice president now directly owns 15,064 shares in the company, valued at approximately $760,732. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jennifer B. Damico sold 4,218 shares of Pfizer stock in a transaction that occurred on Tuesday, June 7th. The stock was sold at an average price of $53.96, for a total value of $227,603.28. Following the transaction, the senior vice president now owns 10,846 shares of the company’s stock, valued at $585,250.16. The disclosure for this sale can be found here. Insiders have sold 41,126 shares of company stock valued at $2,075,003 in the last 90 days. 0.05% of the stock is currently owned by insiders.

Pfizer Stock Down 1.2 %

Shares of Pfizer stock opened at $49.27 on Friday. The business’s 50 day simple moving average is $51.09 and its 200 day simple moving average is $51.10. Pfizer Inc. has a 52-week low of $40.94 and a 52-week high of $61.71. The firm has a market cap of $276.45 billion, a PE ratio of 9.64, a P/E/G ratio of 0.61 and a beta of 0.67. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39.

Pfizer (NYSE:PFE – Get Rating) last announced its earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.95 by $0.09. Pfizer had a return on equity of 44.38% and a net margin of 28.92%. The business had revenue of $27.74 billion for the quarter, compared to analyst estimates of $26.20 billion. During the same quarter last year, the firm earned $1.07 EPS. Pfizer’s revenue for the quarter was up 46.8% compared to the same quarter last year. On average, analysts predict that Pfizer Inc. will post 6.54 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Wednesday, June 29th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 3.25%. The ex-dividend date is Thursday, July 28th. Pfizer’s dividend payout ratio (DPR) is 31.31%.

Pfizer Company Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.